NCT05225740: ETC

Exposure Therapy Consortium (ETC) for Anxiety Sensitivity

Completed NA Last updated 29 April 2025

What this trial tests

NA trial testing Standard Exposure in Elevated Anxiety Sensitivity in 399 participants. Completed in 1 July 2024.

Timeline

1 October 2022

Primary endpoint
1 July 2024

1 July 2024

Quick facts

Lead sponsor	University of Texas at Austin
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	399
Start date	1 October 2022
Primary completion	1 July 2024
Estimated completion	1 July 2024
Sites	12 locations across Israel, Germany, United States, Australia

Drugs / interventions tested

• Standard Exposure
• Stress Management Training
• Enhanced Exposure

Conditions studied

• Elevated Anxiety Sensitivity — all drugs for Elevated Anxiety Sensitivity →

Sponsor

University of Texas at Austin

Who can join

Adults 18 to 70, any sex, with Elevated Anxiety Sensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study seeks to test differences between a single-session large-group format of standard exposure, enhanced exposure, and a control condition in treating anxiety sensitivity. It is hypothesized that 1) participants assigned to either exposure condition will evidence greater reductions in anxiety sensitivity from pre-treatment to posttreatment relative to those in the control condition; 2) participants assigned to the enhanced exposure condition will evidence greater reductions in anxiety sensitivity from pre-treatment to posttreatment relative to those in the standard exposure condition. The investigators will test putative moderators and mechanisms of action. Prior to initiating the study for purposes of data analyses, the investigators will pilot study procedures during Spring 2020.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Improving Exposure Therapy: Rationale and Design of an International Consortium.
   Smits JAJ, Abramowitz JS, Arch JJ, Papini S, et al · · 2024 · cited 4× · PMID 38724129 · DOI 10.1016/j.psc.2024.02.008
2. Exposure therapy consortium: Outcomes of the proof-of-principle study.
   Smits JAJ, Abramowitz JS, Anderson RA, Arch JJ, et al · · 2025 · cited 2× · PMID 39732083 · DOI 10.1016/j.janxdis.2024.102962